穴位埋针对初次配戴角膜塑形镜近视儿童眼表的影响

注册号:

Registration number:

ITMCTR2025000395

最近更新日期:

Date of Last Refreshed on:

2025-02-24

注册时间:

Date of Registration:

2025-02-24

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

穴位埋针对初次配戴角膜塑形镜近视儿童眼表的影响

Public title:

Effect of intradermal needle therapy on the ocular surface of myopic children wearing orthokeratology lenses for the first time

注册题目简写:

English Acronym:

研究课题的正式科学名称:

穴位埋针对初次配戴角膜塑形镜近视儿童眼表的影响

Scientific title:

Effect of intradermal needle therapy on the ocular surface of myopic children wearing orthokeratology lenses for the first time

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

赵育玮

研究负责人:

周行涛

Applicant:

Yuwei Zhao

Study leader:

Xingtao Zhou

申请注册联系人电话:

Applicant telephone:

+86 18019435112

研究负责人电话:

Study leader's telephone:

+86 13816880725

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

zhaoyuwei200017@163.com

研究负责人电子邮件:

Study leader's E-mail:

xingtaozhou@163.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

上海市虹口区甘河路110号

研究负责人通讯地址:

上海市徐汇区宝庆路19号

Applicant address:

110 Ganhe Road Hongkou District Shanghai

Study leader's address:

650 South Wanping Road Xuhui District Shanghai

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

上海中医药大学附属岳阳中西医结合医院

Applicant's institution:

Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Shanghai University of Traditional Chinese MedicineShanghai China

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

[2025]伦审字第(2025002)号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件

批准本研究的伦理委员会名称:

复旦大学附属眼耳鼻喉科医院伦理委员会

Name of the ethic committee:

Ethics Committee of Eye & Ent Hospital of Fudan University

伦理委员会批准日期:

Date of approved by ethic committee:

2025/1/9 0:00:00

伦理委员会联系人:

闫晶超

Contact Name of the ethic committee:

Yan jingchao

伦理委员会联系地址:

上海市徐汇区汾阳路83号

Contact Address of the ethic committee:

83 Fenyang Road Xuhui District Shanghai

伦理委员会联系人电话:

Contact phone of the ethic committee:

021-64377134

伦理委员会联系人邮箱:

Contact email of the ethic committee:

fdeent_ec@126.com

研究实施负责(组长)单位:

复旦大学附属眼耳鼻喉科医院

Primary sponsor:

Eye & Ent Hospital of Fudan University

研究实施负责(组长)单位地址:

上海市汾阳路83号

Primary sponsor's address:

83 Fenyang Road Shanghai

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

上海市

市(区县):

徐汇区

Country:

China

Province:

Shanghai

City:

Xuhui District

单位(医院):

复旦大学附属眼耳鼻喉科医院

具体地址:

上海市汾阳路83号

Institution
hospital:

Eye & Ent Hospital of Fudan University

Address:

83 Fenyang Road Shanghai

经费或物资来源:

上海市卫生健康委员会 上海市中医药管理局 综合医院中西医协同引导项目 中西医协同防治青少年近视的临床研究 ZXXT-202307

Source(s) of funding:

Shanghai Municipal Health Commission Shanghai Municipal Administration of Traditional Chinese Medicine General Hospital collaborative guidance project The clinical study of the cooperation of Chinese and Western medicine to prevent and cure myopia in adolescents ZXXT-202307

研究疾病:

儿童近视与眼表健康

研究疾病代码:

Target disease:

Children's Myopia and Ocular Surface Health

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

探索性研究/预试验

Pilot clinical trial

研究目的:

观察穴位埋针对初次佩戴角膜塑形镜近视儿童眼表的影响。

Objectives of Study:

To observe the effects of intradermal needle therapy on the ocular surface of myopia children who wear orthokeratology lenses for the first time

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

(1)角膜塑形镜试戴通过,即将规律佩戴角膜塑形镜者; (2)年龄8-12岁; (3)睫状肌麻痹后的屈光度数:-4.00 D到-0.50 D,散光≤1.50 D,屈光参差≤1.50 D,矫正视力≧0.8,眼压10-21 mmHg者; (4)患者自愿加入试验且依从性良好并,本人及监护人签定了知情同意书

Inclusion criteria

(1) Those who have passed the trial of orthokeratology lens and will receice orthokeratology regularly; (2) Age 8-12 years old; (3) Cycloplegic spherical equivalent refraction: -4.00D to -0.50D; astigmatism ≤ 1.50D; anisometropia ≤ 1.50D; corrected visual acuity ≧0.8 IOP 10-21 mmHg; (4) The patient voluntarily enrolled in the trial with good compliance and signed an informed consent form by him/herself and his/her guardian.

排除标准:

(1)合并有其他眼部疾病(白内障、先天性视网膜疾病、斜视、弱视等)和全身系统性疾病; (2)眼部活动性病变或眼科手术者; (3)不能配合眼部检查和治疗者; (4)局部穴位皮肤破损、炎症者; (5)佩戴过角膜塑形镜者; (6)1个月内使用过任何近视防控方法者; (7)胶布或金属过敏者。

Exclusion criteria:

(1) With other ocular diseases (such as cataracts congenital retinal diseases strabismus amblyopia etc.) and systemic diseases; (2) With active ocular lesions or who have undergone ophthalmic surgery; (3) Cannot cooperate with ocular examinations and treatments; (4) With skin damage or inflammation at local acupoints; (5) Have worn orthokeratology lenses; (6) Have used any myopia prevention and control methods within one month; (7) Allergic to adhesive tape or metals.

研究实施时间:

Study execute time:

From 2025-03-01

To      2026-03-01

征募观察对象时间:

Recruiting time:

From 2025-03-01

To      2025-09-01

干预措施:

Interventions:

组别:

研究组

样本量:

36

Group:

Study group

Sample size:

干预措施:

穴位埋针联合角膜塑形镜治疗

干预措施代码:

Intervention:

intradermal needle therapy + orthokeratology

Intervention code:

组别:

对照组

样本量:

36

Group:

Control group

Sample size:

干预措施:

常规角膜塑形镜治疗

干预措施代码:

Intervention:

Orthokeratology

Intervention code:

样本总量 Total sample size : 72

研究实施地点:

Countries of recruitment
and research settings:

国家:

中华人民共和国

省(直辖市):

上海市

市(区县):

徐汇区

Country:

China

Province:

Shanghai

City:

Xuhui District

单位(医院):

复旦大学附属眼耳鼻喉科医院

单位级别:

三级甲等

Institution/hospital:

EYE & ENT HOSPITAL OF FUDAN UNIVERSITY

Level of the institution:

Tertiary A-grade

测量指标:

Outcomes:

指标中文名:

医院焦虑抑郁量表

指标类型:

次要指标

Outcome:

Hospital Anxietyand Depression Scale

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

角膜荧光素染色

指标类型:

次要指标

Outcome:

Corneal fluorescein staining

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

泪河高度

指标类型:

次要指标

Outcome:

Tear meniscus height

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

眼红指数

指标类型:

次要指标

Outcome:

Red eye index

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

眼表疾病指数

指标类型:

主要指标

Outcome:

Ocular Surface Disease Index

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

非侵袭性泪膜破裂时间

指标类型:

次要指标

Outcome:

Non-invasive break-up time

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

角膜塑形镜佩戴及摘除成功时间

指标类型:

次要指标

Outcome:

Success time of orthokeratology lens wearing and removal

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

征募研究对象情况:

尚未开始

Not yet recruiting

年龄范围:

最小 8
Min age years
最大 12
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

随机数字由第三方采用计算机生成,采用区组随机化方法,设定区组长度为4,分配比例1:1。

Randomization Procedure (please state who generates the random number sequence and by what method):

The random numbers are computer-generated by a third party using a block randomization method with a block length of 4 and an allocation ratio of 1:1.

盲法:

检测者,统计者盲

Blinding:

The testers and statisticians are blind.

是否共享原始数据:

IPD sharing:

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

NA

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

NA

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

患者的信息(特征)将被记录在CRF表及EXCEL表中,并用代码及缩写来代替参与者的姓名,参与者的其他部分信息(如电话等)也将被匿名以保护参与者的隐私。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

All necessary informations of the participants will be recored in CRFs and EXCEL. In order to protect all participants' privacy, code and abbreviation are used to replace participant's name, and other part of the participant's information (such as phone number) will also be anonymous.

数据管理委员会:

Data Managemen Committee:

No

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

国际传统医学临床试验注册平台 京ICP备07032215号-5 提示:推荐使用IE8.0以上版本 宽屏显示分辨率下使用系统